Announcement on the Capital Increase of Shanghai North Carolina by Subsidiary Peak Pharmaceutical
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 公告编号:临2018-025
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于子公司尖峰药业对上海北卡增资的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l拟增资的控股子公司名称:上海北卡医药技术有限公司
l拟增资金额:5000万元
l出资方式:拟使用自筹资金进行增资
一、对外投资概述
(一)2018年8月3日,本公司控股子公司浙江尖峰药业有限公司(以下简称:尖峰药业)和自然人吴江与康立涛、李倩、郑亚玲及上海北卡医药技术有限公司(以下简称:上海北卡)签订《股权增资协议》,对尖峰药业的控股子公司上海北卡进行增资,增资价格:以坤元资产评估有限公司所出具了《资产评估报告》(坤元评报〔2017〕1-37号)为基础,以2018年1月19日尖峰药业与各方签订的《关于上海北卡医药技术有限公司之增资和股权转让协议》中约定的增资价格为准,确定为:每1元注册资本的认缴价格为11.53元。尖峰药业出资人民币5000万元,自然人吴江出资人民币1000万元,上海北卡的其他股东放弃参与本次增资。
增资完成后,上海北卡注册资本由原来的1755.55万元增加至2275.93万元,其中尖峰药业占61.48%,康立涛占18.42%,李倩占11.46%,郑亚玲4.83%,吴江3.81%。
(二)董事会审议情况
2018年8月3日,公司以通讯方式召开了第十届董事会第五次会议,公司现有九名董事,全部参加了会议,经审议与表决,董事会以9票同意、0票反对、0票弃权审议并通过了该事项。
(三)根据上海证券交易所《股票上市规则》和公司《章程》等有关规定,公司本次对外投资属董事会权限范围,无需提交股东大会审议。该股权收购事项不属于关联交易,也不构成《上市公司重大资产重组管理办法》规定的重大资产重组情况。
二、新增股东的基本情况
吴江,男,中国国籍,住址:浙江省东阳市吴宁街道东岘新村**幢*号,职业:安徽众望董事长兼总经理。
三、投资标的基本情况
(一)上海北卡的基本情况
1、企业名称:上海北卡医药技术有限公司
2、企业性质:有限责任公司
3、注册地:上海市松江区申港路3802号21幢
4、注册日期:2003年10月20日
5、主要办公地点:上海市松江区申港路3802号21幢
6、法定代表人:蒋晓萌
7、注册资本:1755.55万元
8、经营范围:医药和化学专业技术领域内的技术开发、技术咨询、技术服务、技术转让;机械设备、仪器仪表、食用农产品(不含生猪产品)、化肥、饲料添加剂、化工原料及产品(除危险品)批发零售;医药中间体的开发、销售;从事货物及技术的进出口业务。(依法须经批准的项目,经相关部门批准后方可开展经营活动)
9、股东情况
2018年1月,本公司控股子公司尖峰药业与有关各方签订了协议,以收购股权和增资的方式对上海北卡进行投资。详见本公司于2018年1月20日《关于子公司尖峰药业对外投资的公告》。2018年5月,尖峰药业完成了该投资事宜,上海北卡完成了工商变更登记手续,成为尖峰药业的控股子公司。
|
序号 |
股东名称 |
出资额(万元) |
出资比例(%) |
|
1 |
浙江尖峰药业有限公司 |
965.55 |
55.00 |
|
2 |
康立涛 |
419.26 |
23.88 |
|
3 |
李倩 |
260.74 |
14.85 |
|
4 |
郑亚玲 |
110.00 |
6.27 |
|
|
合计 |
1755.55 |
100.00 |
(二)标的公司2017年和2018年半年度财务报表情况
截至2017年末,上海北卡合并资产总额8801.80万元、负债总额7435.37万元、归属于母公司股东权益1366.43万元;2017年合并营业收入9296.47万元、归属于母公司所有者净利润-475.45万元;
截至2018年6月末,上海北卡合并资产总额12828.90 万元、负债总额3346.36万元、归属于母公司股东权益9482.54万元。2018年1-6月合并营业收入8505.53万元、归属于母公司所有者净利润557.63万元。
2017年度的财务数据经具有证券、期货从业资格的天健会计师事务所(特殊普通合伙)审计,2018年半年度的财务数据未经审计。
四、合作协议的主要内容
尖峰药业(甲方1)和吴江(甲方2)(合称甲方)、上海北卡(乙方或标的公司)和原股东康立涛、李倩、郑亚玲(合称丙方)签订了《关于上海北卡医药技术有限公司之增资协议》。协议的主要内容有:
(一)股权增资方案
1.增资价格
三方同意,本次增资的价格以2018年1月19日甲方1和丙方、海南寰太生物医药产业创业投资基金合伙企业、乙方签订的《关于上海北卡医药技术有限公司之增资和股权转让协议》中约定的增资价格为准,本协议项下的增资价格为:每1元注册资本的认缴价格为11.53元。
2.甲方增资金额
2.1本协议项下,甲方1本次增资额为人民币5000万元。其中,433.65万元记入注册资金,4566.35万元记入资本公积。
甲方2本次增资额为人民币1000万元。其中,86.73万元记入注册资金,913.27万元记入资本公积。
2.2本次增资完成后,乙方的注册资本由1755.55万元增加至2275.93万元,甲方1持有乙方61.48%股权、甲方2持有乙方3.81%股权。
3. 本次增资后乙方的股权结构变化
本次增资完成后,乙方的股东持股比例及出资情况如下:
|
股东名称 |
出资额(万元) |
持有比例(%) |
出资方式 |
|
浙江尖峰药业有限公司 |
1399.20 |
61.48 |
货币 |
|
康立涛 |
419.26 |
18.42 |
货币 |
|
李倩 |
260.74 |
11.46 |
货币 |
|
郑亚玲 |
110.00 |
4.83 |
货币 |
|
吴江 |
86.73 |
3.81 |
货币 |
|
合计 |
2275.93 |
100.00 |
|
4.增资款
本协议项下的增资款,由甲方于本协议生效后的30个工作日内一次性支付至乙方指定的验资账户。
5.股份转让限制
甲2同意,通过协议转让等方式出让公司股份时,视同为“原个人股东”,共同遵守《关于上海北卡医药技术有限公司之增资和股权转让协议》(2018年1月19日签署)的约定。
6.反稀释条款
各方约定,在甲方投资入股后五年内,若乙方公司进行后续增资,其增资价格不得低于甲方本轮增资的价格。
(二)增资手续办理
1. 本协议正式签署之前或当日,乙方应召开股东会,审议本次股权增资事宜。
2. 增资款到位后的30个工作日内,乙方应完成增资的全部法律手续,包括但不限于变更股东名册、修改公司章程、办理工商变更登记手续等。
(三)违约责任
若任何一方违反本协议的约定,给守约方造成实际损失或者丧失投资/融资机会,守约方可要求违约方赔偿经济损失。
(四)争议解决
因本协议所引起的或与本协议有关的任何争议,应协商解决,协商不成的,任何一方都可将争议提交金华市仲裁委员会,根据该会仲裁规则在金华市进行仲裁。
(五)协议的生效、变更与解除
1.本协议的生效需同时满足如下条件:
1.1本协议经协议各方自然人本人或法人的法定代表人签字并盖章;
1.2乙方股东会审议通过本次增资事宜。
1.3甲1的有权部门通过本次增资事宜。
五、本次增资对公司的影响
(一)本次合作是公司加强医药业务板块发展的具体实施,本次增资有利于提升上海北卡的综合实力,增加上海北卡的资金流,为其收购安徽众望制药有限公司提供资金保障。
(二)本次对外投资的资金来源为公司的自筹资金。
(三)本次对外投资对公司当期利润不会造成重大影响。
六、备查文件
公司第十届董事会第五次会议决议
特此公告。
浙江尖峰集团股份有限公司董事会
2018年8月3日
More information
Recently, it was learned from the competent department that the "ERP/MES full-process informatization" project of Jianfeng Pharmaceutical Company has been included in the list of key projects of "integration of industrialization and industrialization" in Jinhua City, and has now entered the publicity period. In order to speed up the in-depth integration of informatization and industrialization, according to the evaluation criteria in Jinhua City's "Several Opinions on Accelerating Informatization Construction" and "Jinhua City Informatization and Industrialization Integration Key Project Management Measures", 148 projects were included in 2017 Jinhua City's "Integration of Industrialization and Industrialization" key projects. The "ERP/MES Full Process Informatization" project of Jianfeng Pharmaceutical Co., Ltd. was finally included in the list after being recommended, material reviewed and expert reviewed by Jinhua Economic and Information Committee. The ERP-level subsystems of ERP/MES full-process informatization project include sales system, procurement system, MRP system, GMPQbD system, connecting UFIDA financial software and HR system. MES-level subsystems include industrial data acquisition and monitoring system, GAMP/MES system, eBPR (electronic batch production record system), cGMP quality assurance system, QC/eBTR(QC process and electronic batch inspection record system), LIMS system, etc. After the construction is completed, the visualization of drug production process and the collection and integration of industrial data will be realized. Realize the electronization of drug production process parameters, electronic batch production and inspection records; the realization of big data integration of industrial data and information will also be in line with the regulatory concept of GMP data integrity and quality traceability to the greatest extent. The establishment of a unified enterprise information platform will eliminate information islands and realize data one.
2020
07-31
The company's first-half profit record high
According to the 15th meeting of the ninth board of directors of the company on August 25, in the first half of 2017, the company achieved a net profit of 240.5357 million yuan, the highest level in half a year's history. In the first half of 2017, the company focused on the general work policy of "grasping trends, precise development, strengthening management, and improving efficiency", grasping the opportunities brought by economic structure optimization and industrial upgrading, strengthening lean production and management improvement internally, and actively exploring externally Develop new opportunities and continue to promote the "three reductions and three improvements" work. Through the joint efforts of all employees of the company, the best semi-annual performance in history has been achieved. As of the end of June 2017, the company's total assets were 4.226 billion yuan and net assets were 2.511 billion yuan; the company achieved total operating income of 1,305.9327 million yuan, an increase of 18.42 percent over the same period last year, and net profit attributable to owners of the parent company was 240.5357 million yuan, an increase of 132.11 percent over the same period last year. Earnings per share are 0.7 yuan. In the second half of the year, the company will continue to focus on the annual business plan, carry out in-depth work of "three reductions and three improvements", further do a good job in internal control, prevent business risks, and further do a good job in safety and environmental protection. we will further develop and improve the complementary relatively diversified main business structure and constantly enhance the company's core competitiveness. The 15th meeting of the 9th board of directors held on August 25 was presided over by Jiang Xiaomeng, chairman of the group company. Four proposals and reports including the 2017 semi annual report and the proposal on the change of the company's accounting policy were deliberated and passed. on the same day, the 12th meeting of the eighth board of supervisors was held,
2020
07-31
General Manager Yu Jianhong to Yunnan Peak to Guide Work
On August 23, Yu Jianhong, general manager of the group company, went to Yunnan Jianfeng cement company for investigation and guidance, and put forward requirements for the key work in the last few months of this year. At the peak of Yunnan Province, Yu Jianhong went deep into the production site to learn more about the current production and operation situation, and convened the middle-level and above management backbones to have in-depth exchanges and discussions with everyone on the problems existing in work efficiency changes, personnel stability, current production and management after the implementation of post optimization and re-organization. Since the beginning of this year, Yunnan's peak production and sales volume, profits and various technological and technical indicators have been relatively ideal. The kiln output in April has also reached the best level since it was put into production. The development and maintenance of the market, the environmental management of the factory area, and the professional quality and mental state of cadres and workers have also been greatly improved. While fully affirming the above achievements, Yu Jianhong pointed out that as the homogenization of the cement market becomes more and more serious, the market changes faster and faster. If we can't recognize the situation and seize the opportunity, enterprises will face more and more problems. In this case, the management backbone should give full play to the role of the backbone, quickly change the management concept, and strive to improve the competitiveness of enterprises. In view of the focus of work in the last four months of this year, Yu Jianhong put forward the following requirements for Yunnan Jianfeng: break the inherent concept of post functions and responsibilities, set up posts and organizational structures around logistics, people flow and capital flow, and cultivate and forge a team that can fight well. To further implement the training of job skills and quality, managers should take the lead in strengthening their own learning and formulate annual, monthly and weekly training plans, through the combination of internal and external training, theory and practice.
2020
07-30
General Manager Yu Jianhong to Yunnan Peak to Guide Work
On August 23, Yu Jianhong, general manager of the group company, went to Yunnan Jianfeng cement company for investigation and guidance, and put forward requirements for the key work in the last few months of this year. At the peak of Yunnan Province, Yu Jianhong went deep into the production site to learn more about the current production and operation situation, and convened the middle-level and above management backbones to have in-depth exchanges and discussions with everyone on the problems existing in work efficiency changes, personnel stability, current production and management after the implementation of post optimization and re-organization. Since the beginning of this year, Yunnan's peak production and sales volume, profits and various technological and technical indicators have been relatively ideal. The kiln output in April has also reached the best level since it was put into production. The development and maintenance of the market, the environmental management of the factory area, and the professional quality and mental state of cadres and workers have also been greatly improved. While fully affirming the above achievements, Yu Jianhong pointed out that as the homogenization of the cement market becomes more and more serious, the market changes faster and faster. If we can't recognize the situation and seize the opportunity, enterprises will face more and more problems. In this case, the management backbone should give full play to the role of the backbone, quickly change the management concept, and strive to improve the competitiveness of enterprises. In view of the focus of work in the last four months of this year, Yu Jianhong put forward the following requirements for Yunnan Jianfeng: break the inherent concept of post functions and responsibilities, set up posts and organizational structures around logistics, people flow and capital flow, and cultivate and forge a team that can fight well. To further implement the training of job skills and quality, managers should take the lead in strengthening their own learning and formulate annual, monthly and weekly training plans, through the combination of internal and external training, theory and practice.
2020
07-31
Spike Pharmaceuticals set out to explore a new sales model
Agency and Terminal Link Production and Chain Cooperation Spike Pharmaceuticals to Explore New Sales Models From August 16 to 21, the 2017 China Pharmaceutical Retail Industry Information Conference (hereinafter referred to as "Xipu Conference") with the theme of "Building a Blueprint-Market Awakening Focusing on Demand" was held in Boao, Hainan. Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, and relevant leaders of Spike Health, pharmaceutical sales company and Spike Pharma pharmacy were invited to attend the event, to create a new sales model "road". This year coincides with the 10th anniversary of the Western Conference. More than 1200 mainstream chain pharmacies, more than 800 brand pharmaceutical industries, more than 100 cross-border affiliated institutions, more than 130 top domestic and foreign capital institutions, more than 60 representatives of authoritative media, and authoritative experts in the industry, with nearly 4000 people gathered in Boao. The meeting combed the context of the pharmaceutical retail industry in the past ten years, discussed the development of the industry in the new decade, and built a new blueprint for the industry. During the meeting, Huang Jinlong led the peak participants to have in-depth exchanges with the organizers of the conference and industry experts on issues such as the impact of national policies such as the brand strategy of enterprises, the role of brand enterprises in the industry, medical reform, prescription outflow, etc. on the original sales mode of pharmaceutical enterprises. He also had extensive contact with pharmaceutical counterparts and terminal chains, listened to front-line sales experience, collected relevant information on terminal chains, and collected market trends of the top 100 chains. In the past ten years, the scale of drug retail sales in China has increased from 143 billion yuan to 337.7 billion yuan, and the chain rate has increased from 35.3 percent to 49.4 percent.
2020
07-31
General Manager Yu Jianhong to Yunnan Peak to Guide Work
On August 23, Yu Jianhong, general manager of the group company, went to Yunnan Jianfeng cement company for investigation and guidance, and put forward requirements for the key work in the last few months of this year. At the peak of Yunnan Province, Yu Jianhong went deep into the production site to learn more about the current production and operation situation, and convened the middle-level and above management backbones to have in-depth exchanges and discussions with everyone on the problems existing in work efficiency changes, personnel stability, current production and management after the implementation of post optimization and re-organization. Since the beginning of this year, Yunnan's peak production and sales volume, profits and various technological and technical indicators have been relatively ideal. The kiln output in April has also reached the best level since it was put into production. The development and maintenance of the market, the environmental management of the factory area, and the professional quality and mental state of cadres and workers have also been greatly improved. While fully affirming the above achievements, Yu Jianhong pointed out that as the homogenization of the cement market becomes more and more serious, the market changes faster and faster. If we can't recognize the situation and seize the opportunity, enterprises will face more and more problems. In this case, the management backbone should give full play to the role of the backbone, quickly change the management concept, and strive to improve the competitiveness of enterprises. In view of the focus of work in the last four months of this year, Yu Jianhong put forward the following requirements for Yunnan Jianfeng: break the inherent concept of post functions and responsibilities, set up posts and organizational structures around logistics, people flow and capital flow, and cultivate and forge a team that can fight well. To further implement the training of job skills and quality, managers should take the lead in strengthening their own learning and formulate annual, monthly and weekly training plans, through the combination of internal and external training, theory and practice.
2020
07-31